Mabpharm Ltd 02181
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 0.38
- Day Range
- HKD 0.36–0.36
- 52-Week Range
- HKD 0.27–0.79
- Bid/Ask
- HKD 0.36 / HKD 0.41
- Market Cap
- HKD 1.48 Bil
- Volume/Avg
- 10,000 / 83,417
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 347
- Website
- http://www.mabpharm.cn
Comparables
Valuation
Metric
|
02181
|
02171
|
01167
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.18 | 1.87 | 1.53 |
Price/Sales | 16.03 | — | 21.55 |
Price/Cash Flow | — | — | — |
Price/Earnings
02181
02171
01167
Financial Strength
Metric
|
02181
|
02171
|
01167
|
---|---|---|---|
Quick Ratio | 0.69 | 9.49 | 5.67 |
Current Ratio | 1.08 | 9.55 | 5.70 |
Interest Coverage | −20.87 | −174.85 | −47.87 |
Quick Ratio
02181
02171
01167
Profitability
Metric
|
02181
|
02171
|
01167
|
---|---|---|---|
Return on Assets (Normalized) | −20.43% | −28.70% | −21.84% |
Return on Equity (Normalized) | −79.65% | −35.29% | −31.75% |
Return on Invested Capital (Normalized) | −38.37% | −35.38% | −26.98% |
Return on Assets
02181
02171
01167
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zbqtyzvjb | Kjp | $586.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Msmtdvgv | Tmkvxk | $115.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tljyqlpc | Hmjgp | $108.2 Bil | |
MRNA
| Moderna Inc | Tnnvdrlr | Rmnv | $54.0 Bil | |
BNTX
| BioNTech SE ADR | Dnymcmwc | Hcmkf | $21.8 Bil | |
ARGX
| argenx SE ADR | Zwqxfcdv | Kpb | $21.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pqshcmpjv | Mzskjfs | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rwkxkjjk | Cwqkmjl | $14.6 Bil | |
INCY
| Incyte Corp | Ylcxyms | Wgzzfdw | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yjmcztjxnv | Kqcyll | $12.3 Bil |